Novo Nordisk

News

Pharma group slams Hims & Hers over Super Bowl GLP-1 ad

Partnership for Safe Medicines claims the Hims & Hers ad for compounded weight-loss drug semaglutide, due to run during the Super Bowl, is "reckless."

News

Martin Holst Lange, Novo Nordisk's head of development

Novo charts course ahead for CagriSema after lacklustre data

After its first phase 3 trial of obesity hope CagriSema left investors dissatisfied, Novo Nordisk has a plan to get the programme back on track.

News

Novo rises on Wegovy sales leap, but warns of a slowdown

Novo Nordisk is expecting greater competition and pricing pressure in the obesity and diabetes sectors this year.

News

Ozempic is first GLP-1 drug FDA-approved for kidney disease

Novo Nordisk's Ozempic has become the first drug in the GLP-1 class to be cleared to prevent worsening kidney disease in type 2 diabetics.

News

Novo Nordisk leaps on new obesity drug data

Shares in Novo Nordisk have risen sharply on new weight-loss data with an injectable formulation of new obesity candidate amycretin.

News

High-dose semaglutide ramps up weight loss, says Novo

Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.

Pharma group slams Hims & Hers over Super Bowl GLP-1 ad

Novo charts course ahead for CagriSema after lacklustre data

Novo rises on Wegovy sales leap, but warns of a slowdown

Ozempic is first GLP-1 drug FDA-approved for kidney disease

Novo Nordisk leaps on new obesity drug data

High-dose semaglutide ramps up weight loss, says Novo

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

Novo Nordisk

Editor's Picks